Esperion Therapeutics Inc. (Nasdaq: ESPR) updated its Phase 3 strategy for ETC-1002 in response to the Food and Drug Administration’s End-of-Phase 2 Meeting Minutes. Shares of the biopharmaceutical plummeted $16.76 to close at $18.33.